The U.S. hormone therapy market is expanding due to rising healthcare costs, an aging population, and patient-centered care trends favoring home-based treatments. Opportunities include user-friendly ...

More Americans are turning to peptides for muscle building, skin rejuvenation, and to try and live longer even though the ...

Ascendis Pharma’s consensus analyst price target has recently increased from $245.61 to $258.77 per share. This reflects a renewed sense of optimism as Yorvipath’s uptake accelerates and real-world ...